CN118562003A - Fcrn抗体及其使用方法 - Google Patents

Fcrn抗体及其使用方法 Download PDF

Info

Publication number
CN118562003A
CN118562003A CN202410661144.5A CN202410661144A CN118562003A CN 118562003 A CN118562003 A CN 118562003A CN 202410661144 A CN202410661144 A CN 202410661144A CN 118562003 A CN118562003 A CN 118562003A
Authority
CN
China
Prior art keywords
sequence
seq
cdr
fcrn
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410661144.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·克里
D·J·金
L·E·凌
J·米多尔三世
S·罗伊
A·曼宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of CN118562003A publication Critical patent/CN118562003A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
CN202410661144.5A 2015-01-30 2016-01-29 Fcrn抗体及其使用方法 Pending CN118562003A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562110071P 2015-01-30 2015-01-30
US62/110071 2015-01-30
US201562258082P 2015-11-20 2015-11-20
US62/258082 2015-11-20
PCT/US2016/015720 WO2016123521A2 (en) 2015-01-30 2016-01-29 Fcrn antibodies and methods of use thereof
CN201680008485.6A CN107567460B (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680008485.6A Division CN107567460B (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法

Publications (1)

Publication Number Publication Date
CN118562003A true CN118562003A (zh) 2024-08-30

Family

ID=56544538

Family Applications (13)

Application Number Title Priority Date Filing Date
CN202410661131.8A Pending CN118638229A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661136.0A Pending CN118638230A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661144.5A Pending CN118562003A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661152.XA Pending CN118667015A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661147.9A Pending CN118667012A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661138.XA Pending CN118652337A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661133.7A Pending CN118667009A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661140.7A Pending CN118667010A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661149.8A Pending CN118667013A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661142.6A Pending CN118667011A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202110605791.0A Active CN113384693B (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661150.0A Pending CN118667014A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN201680008485.6A Active CN107567460B (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202410661131.8A Pending CN118638229A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661136.0A Pending CN118638230A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法

Family Applications After (10)

Application Number Title Priority Date Filing Date
CN202410661152.XA Pending CN118667015A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661147.9A Pending CN118667012A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661138.XA Pending CN118652337A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661133.7A Pending CN118667009A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661140.7A Pending CN118667010A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661149.8A Pending CN118667013A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661142.6A Pending CN118667011A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202110605791.0A Active CN113384693B (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN202410661150.0A Pending CN118667014A (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法
CN201680008485.6A Active CN107567460B (zh) 2015-01-30 2016-01-29 Fcrn抗体及其使用方法

Country Status (21)

Country Link
US (3) US10676526B2 (OSRAM)
EP (2) EP4286011A3 (OSRAM)
JP (2) JP6853178B2 (OSRAM)
KR (3) KR102792441B1 (OSRAM)
CN (13) CN118638229A (OSRAM)
AU (2) AU2016211280B2 (OSRAM)
DK (1) DK3250610T3 (OSRAM)
ES (1) ES2962824T3 (OSRAM)
FI (1) FI3250610T3 (OSRAM)
HR (1) HRP20231399T1 (OSRAM)
HU (1) HUE063778T2 (OSRAM)
IL (1) IL252837B (OSRAM)
LT (1) LT3250610T (OSRAM)
NZ (1) NZ772383A (OSRAM)
PL (1) PL3250610T3 (OSRAM)
PT (1) PT3250610T (OSRAM)
RS (1) RS64768B1 (OSRAM)
SG (2) SG10202007232WA (OSRAM)
SI (1) SI3250610T1 (OSRAM)
SM (1) SMT202300365T1 (OSRAM)
WO (1) WO2016123521A2 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3087095T (lt) 2013-12-24 2019-09-10 Argenx Bvba Fcrn-antagonistai ir naudojimo būdai
MX2016014355A (es) * 2014-06-12 2017-01-27 Hoffmann La Roche Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado.
CN118638229A (zh) 2015-01-30 2024-09-13 动量制药公司 Fcrn抗体及其使用方法
WO2018023136A1 (en) * 2016-07-29 2018-02-01 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
CN110785186A (zh) * 2017-06-15 2020-02-11 Ucb生物制药有限责任公司 用于治疗免疫性血小板减少的方法
JP7422659B2 (ja) 2017-12-08 2024-01-26 アルジェニクス ビーブイ 全身型重症筋無力症治療のためのＦｃＲｎアンタゴニストの使用
JP7420720B2 (ja) * 2017-12-13 2024-01-23 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
MX2020013195A (es) 2018-06-08 2021-02-26 Argenx Bvba Composiciones y metodos para el tratamiento de la trombocitopenia inmunitaria.
MX2021000790A (es) * 2018-07-20 2021-07-21 Momenta Pharmaceuticals Inc Composiciones de anticuerpos del receptor neonatal para fc y metodos de uso de las mismas.
IL280278B2 (en) * 2018-07-20 2025-10-01 Momenta Pharmaceuticals Inc Fcrn antibody preparations
EP3866933A1 (en) 2018-10-16 2021-08-25 UCB Biopharma SRL Method for the treatment of myasthenia gravis
EP3980063A1 (en) 2019-06-07 2022-04-13 Argenx BVBA Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
CA3148826A1 (en) * 2019-08-01 2021-02-04 Janssen Biotech, Inc. Fcrn antibodies and methods of use thereof
TW202132346A (zh) * 2019-11-19 2021-09-01 瑞士商依牧諾萬科學有限公司 使用抗-fcrn抗體治療溫抗體型自體免疫性溶血性貧血之方法
FI4087875T3 (fi) 2020-01-08 2024-10-25 argenx BV Vastasyntyneen ihmisen Fc-reseptorin (FcRn) antagonisteja pemfigus-häiriöiden hoitoon
EP4240417A4 (en) * 2020-11-06 2024-10-02 Momenta Pharmaceuticals, Inc. ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF
EP4287828A4 (en) * 2021-02-02 2025-01-15 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric fcrn
EP4384548A4 (en) * 2021-08-13 2024-11-13 Staidson (Beijing) Biopharmaceuticals Co., Ltd. ANTIBODIES SPECIFICALLY RECOGNIZING FCRN AND THEIR USES
CN116234827A (zh) * 2021-09-03 2023-06-06 舒泰神（北京）生物制药股份有限公司 特异性识别FcRn的抗体及其应用
KR20250018382A (ko) 2022-05-30 2025-02-05 한올바이오파마주식회사 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편
WO2023242372A1 (en) 2022-06-15 2023-12-21 argenx BV Fcrn/hsa binding molecules and methods of use
WO2024163894A1 (en) 2023-02-04 2024-08-08 Momenta Pharmaceuticals, Inc. Compositions and methods for treating hemolytic disease of the fetus and newborn
TW202527982A (zh) 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2025186787A1 (en) 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007924A (es) 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
EP1660128A4 (en) * 2003-08-08 2009-01-21 Univ New York State Res Found ANTI-CORR ANTI-BODIES FOR THE TREATMENT OF AUTO / ALLO-IMMUNE DISORDERS
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
KR100996801B1 (ko) 2005-03-08 2010-11-25 파마시아 앤드 업존 캄파니 엘엘씨 항-ＭＡｄＣＡＭ 항체 조성물
WO2007087289A2 (en) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
CN101421297A (zh) * 2006-02-17 2009-04-29 森托尼克斯制药有限公司 阻断lgG对FcRn的结合的肽
JP2009529339A (ja) * 2006-03-13 2009-08-20 アブリンクス エン．ヴェー． Ｉｌ−６を標的とするアミノ酸配列およびそれを含みｉｌ−６介在シグナル伝達に関連する疾患および疾病を治療するポリペプチド
BRPI0910622A2 (pt) * 2008-04-25 2020-03-10 Dyax Corp. ANTICORPOS CONTRA FcRn E USOS DOS MESMOS
CA2766065C (en) 2009-06-30 2020-07-21 Research Development Foundation Immunoglobulin fc polypeptides
ES2748583T3 (es) * 2011-06-02 2020-03-17 Dyax Corp Proteínas de unión al receptor Fc
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US20130323242A1 (en) 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
EP2934587A4 (en) 2012-12-18 2016-08-03 Merck Sharp & Dohme Liquid formulations for an anti-TNF-alpha-antibody
ES2802274T3 (es) 2013-05-02 2021-01-18 Momenta Pharmaceuticals Inc Glicoproteínas sialiladas
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
CN118638229A (zh) 2015-01-30 2024-09-13 动量制药公司 Fcrn抗体及其使用方法
IL295425A (en) * 2015-03-09 2022-10-01 argenx BV Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
ES2956662T3 (es) 2015-05-12 2023-12-26 Syntimmune Inc Anticuerpos anti-FcRn humanizados con afinidad madurada
WO2018023136A1 (en) * 2016-07-29 2018-02-01 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
JP7422659B2 (ja) 2017-12-08 2024-01-26 アルジェニクス ビーブイ 全身型重症筋無力症治療のためのＦｃＲｎアンタゴニストの使用
JP7420720B2 (ja) 2017-12-13 2024-01-23 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
IL280278B2 (en) 2018-07-20 2025-10-01 Momenta Pharmaceuticals Inc Fcrn antibody preparations
MX2021000790A (es) 2018-07-20 2021-07-21 Momenta Pharmaceuticals Inc Composiciones de anticuerpos del receptor neonatal para fc y metodos de uso de las mismas.

Also Published As

Publication number Publication date
EP4286011A3 (en) 2024-02-14
CN113384693B (zh) 2025-07-04
SG10202007232WA (en) 2020-09-29
LT3250610T (lt) 2023-09-25
EP4286011A2 (en) 2023-12-06
KR20230007545A (ko) 2023-01-12
HUE063778T2 (hu) 2024-01-28
NZ733097A (en) 2024-07-05
EP3250610B1 (en) 2023-08-09
SI3250610T1 (sl) 2023-11-30
AU2016211280B2 (en) 2021-11-25
SMT202300365T1 (it) 2023-11-13
CN107567460B (zh) 2021-04-23
RS64768B1 (sr) 2023-11-30
JP2018504907A (ja) 2018-02-22
CN118667009A (zh) 2024-09-20
FI3250610T3 (fi) 2023-11-01
CN113384693A (zh) 2021-09-14
PT3250610T (pt) 2023-11-13
CN118638230A (zh) 2024-09-13
KR20170109020A (ko) 2017-09-27
CA2972822A1 (en) 2016-08-04
KR102792441B1 (ko) 2025-04-08
KR102483016B1 (ko) 2023-01-03
WO2016123521A2 (en) 2016-08-04
US11732047B2 (en) 2023-08-22
CN107567460A (zh) 2018-01-09
DK3250610T3 (da) 2023-10-30
WO2016123521A3 (en) 2016-09-22
JP6853178B2 (ja) 2021-03-31
CN118667013A (zh) 2024-09-20
EP3250610A2 (en) 2017-12-06
JP7224382B2 (ja) 2023-02-17
KR20250052465A (ko) 2025-04-18
US20180016334A1 (en) 2018-01-18
CN118638229A (zh) 2024-09-13
CN118667011A (zh) 2024-09-20
US20200299382A1 (en) 2020-09-24
JP2021061854A (ja) 2021-04-22
IL252837B (en) 2021-10-31
BR112017015287A2 (pt) 2018-01-16
CN118652337A (zh) 2024-09-17
CN118667010A (zh) 2024-09-20
EP3250610A4 (en) 2018-08-22
PL3250610T3 (pl) 2024-01-29
CN118667015A (zh) 2024-09-20
CN118667012A (zh) 2024-09-20
US20240158508A1 (en) 2024-05-16
IL252837A0 (en) 2017-08-31
AU2016211280A1 (en) 2017-07-13
US10676526B2 (en) 2020-06-09
SG11201705475QA (en) 2017-08-30
AU2022201145B2 (en) 2024-11-14
HRP20231399T1 (hr) 2024-02-16
AU2022201145A1 (en) 2022-03-17
NZ772383A (en) 2024-11-29
CN118667014A (zh) 2024-09-20
ES2962824T3 (es) 2024-03-21

Similar Documents

Publication Publication Date Title
AU2022201145B2 (en) FcRn antibodies and methods of use thereof
KR102505995B1 (ko) FcRn 항체 및 이의 사용 방법
HK40103769A (en) Fcrn antibodies and methods of use thereof
CA2972822C (en) Fcrn antibodies and methods of use thereof
HK1247218B (en) Fcrn antibodies and methods of use thereof
HK1247218A1 (en) Fcrn antibodies and methods of use thereof
BR122021007991B1 (pt) Uso de anticorpos que se ligam a fcrn humana
BR112017015287B1 (pt) Anticorpos isolados que se ligam a fcrn humano, e composição farmacêutica

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination